Skip to search formSkip to main contentSkip to account menu

MK-7009

Known as: MK 7009, MK7009 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Indoles
vaniprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.
2015
2015
Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients
Background Some drugs that are actively taken up into the liver exhibit greater than dose proportional increases in plasma… 
Highly Cited
2012
Highly Cited
2012
Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.
A highly efficient synthesis of Vaniprevir (MK-7009) has been accomplished in nine linear steps and 55% overall yield. The key… 
Highly Cited
2012
Highly Cited
2012
Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C: A randomized phase II study
Vaniprevir (MK‐7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the… 
2011
2011
Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycle.
Development of a practical synthesis of MK-7009, a 20-membered [corrected] macrocycle, is described. A variety of ring-closing… 
Highly Cited
2011
Highly Cited
2011
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
BACKGROUND & AIMS The hepatitis C virus (HCV) genotype influences efficacy of interferon (IFN)-based therapy. HCV protease… 
Highly Cited
2010
Highly Cited
2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular… 
Highly Cited
2010
Highly Cited
2010
Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
ABSTRACT In order to assess the natural variation in susceptibility to hepatitis C virus (HCV) NS3 protease inhibitors (PIs… 
Highly Cited
2010
Highly Cited
2010
Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents
ABSTRACT Efforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are… 
Highly Cited
2009
Highly Cited
2009
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
ABSTRACT The administration of hepatitis C virus (HCV) NS3/4A protease inhibitors to patients with chronic HCV infections has… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License